Characteristics | Mean (SD) or % | |
---|---|---|
RA, n = 1270 | Controls, n = 186 | |
Demographic | ||
Age at enrollment, yrs (SD) | 63.6 (11.4) | 56.5 (12.5) |
Male, % | 90.5 | 67.4 |
Race, % | ||
White | 77.6 | 93.0 |
African American | 16.5 | |
Other | 5.8 | |
≥ High school education, % | 84.0 | |
Smoking status, % | ||
Never | 20.3 | |
Former | 52.0 | |
Current | 27.7 | |
Body mass index, kg/m2 (SD) | 28.3 (5.6) | |
Comorbidity count (0–9) (SD) | 3.2 (1.8) | |
RA-related measures at enrollment | ||
Disease duration at enrollment, yrs | 12.2 (11.5) | |
HLA-DRB1 SE-positive, % | 71.7 | |
ACPA-positive, % | 75.6 | |
Rheumatoid factor-positive, % | 80.5 | |
Subcutaneous nodules, % | 36.1 | |
hsCRP, mg/l | 13.0 (20.1) | |
hsCRP ≥ 3 mg/l, % | 69.5 | |
ESR, mm/h | 26.0 (22.2) | |
Tender joint count (0 to 28) | 5.0 (6.7) | |
Swollen joint count (0 to 28) | 4.1 (5.4) | |
Pain (0 to 10) | 4.5 (2.9) | |
Physician global (0 to 100 mm) | 36.4 (22.8) | |
Patient global (0 to 100 mm) | 41.1 (25.6) | |
Multidimensional HAQ (0 to 3) | 0.93 (0.60) | |
DAS28 category, % | ||
< 2.6 (remission) | 22.9 | |
≥ 2.6 and < 3.2 (low activity) | 14.6 | |
≥ 3.2 and < 5.1 (moderate activity) | 40.8 | |
≥ 5.1 (high activity) | 21.8 | |
RAPID-3 score | 2.6 (1.4) | |
Prednisone use | 43.2 | |
Methotrexate use | 55.6 | |
Anti-TNF-α use | 29.4 | |
CD14 genotypes | ||
rs2569190 (CD14/–260), % | ||
GG | 30.0 | |
AG | 49.4 | |
AA | 20.7 | |
rs5744455 (CD14/–651), % | ||
CC | 64.1 | |
CT | 31.5 | |
TT | 4.5 | |
rs2915863 (CD14/–1720), % | ||
TT | 39.7 | |
CT | 45.2 | |
CC | 15.1 | |
rs2569193 (CD14/–2838), % | ||
GG | 54.5 | |
AG | 38.4 | |
AA | 7.2 |
SE: shared epitope; ACPA: anticitrullinated protein antibody; hsCRP: high sensitivity C-reactive protein; ESR: erythrocyte sedimentation rate; MD-HAQ: Multidimensional Health Assessment Questionnaire; DAS: Disease Activity Score; RAPID: Routine Assessment of Patient Index Data; TNF: tumor necrosis factor.